Abstract
The CKII inhibitory compound was purified from the fruit of Xanthium strumarium by organic solvent extraction and silica gel chromatography. The inhibitory compound was identified as 3,4-dihydroxybenzaldehyde by analysis with FT-IR, FAB-Mass, EI-Mass, 1H-NMR and 13C-NMR. 3,4-dihydroxybenzaldehyde inhibited the phosphotransferase activity of CKII with IC50 of about 783 μM. Steady-state studies revealed that the inhibitor acts as a competitive inhibitor with respect to the substrate ATP. A value of 138.6 μM was obtained for the apparent Ki. Concentration of 300 μM 3,4-dihydroxybenzaldehyde caused 50% growth inhibition of human cancer cell U937. 3,4-dihydroxybenzaldehyde-induced cell death was characterised with the cleavage of poly(ADP-ribose) polymerase and procaspase-3. Furthermore, the inhibitor induced the fragmentation of DNA into multiples of 180 bp, indicating that it triggered apoptosis. This induction of apoptosis by 3,4-dihydroxybenzaldehyde was also confirmed by using flow cytometry analysis. Since CKII is involved in cell proliferation and oncogenesis, these results suggest that 3,4-dihydroxybenzaldehyde may function by inhibiting oncogenic disease, at least in part, through the inhibition of CKII activity.
Original language | English |
---|---|
Pages (from-to) | 1441-1450 |
Number of pages | 10 |
Journal | Natural Product Research |
Volume | 22 |
Issue number | 16 |
DOIs | |
State | Published - 10 Nov 2008 |
Keywords
- 3,4-dihydroxybenzaldehyde
- Anti-cancer drug
- Apoptosis
- Enzyme inhibitor
- Human leukaemia cells
- Protein kinase CKII
- Xanthium strumarium